News

L-DOS47 is the company’s first immunoconjugate based drug candidate in development based on its DOS47 platform technology designed to use a new approach to amend the microenvironmental conditions

The phase 1/2 open-label, multi-center, clinical trial is for patients with CD30-expressing relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas (NHL), including diffuse large B-cell lymphoma (DLBCL), peripheral

The ongoing phase-2 clinical trial investigates the safety and efficacy of ACP-01, which uses angiogenic progenitor cells to combat the life-threatening complications of CLI. These proprietary cells are

The agreement was executed based on a series of studies using validated animal models of CIPN exposed to unique cannabinoid-based therapies conducted in the lab of Dr. Kenneth

The amendment includes a change in primary endpoint to overall survival to enable a potential registration opportunity for MM-121. Merrimack president and CEO Robert Mulroy said: "We believe

Vanda president and CEO Mihael Polymeropoulos said: "The MAA validation demonstrates Vanda’s commitment to offer another option to the healthcare community to treat a severe, disabling mental disorder.

In the pivotal clinical trial, rVIII-SingleChain met all primary endpoints. Hemophilia A is a congenital bleeding disorder characterized by deficient or defective factor VIII; nearly all affected patients

T2D is a chronic syndrome that is caused due to dysregulation of blood sugar levels. The research collaboration is expected to address underlying pathologies of diabetes, which is

Under the Javelin Ovarian 200 open-label, parallel group, global study, the companies will assess the superiority of avelumab as monotherapy or in combination with pegylated liposomal doxorubicin (PLD)